Insider Transactions in Q1 2022 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q1 2022)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 28
2022
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
908
-2.16%
|
$92,616
$102.62 P/Share
|
Feb 28
2022
|
John W Kozarich Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,335
+14.83%
|
$88,020
$12.53 P/Share
|
Feb 15
2022
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,407
-2.44%
|
$419,061
$123.68 P/Share
|
Feb 15
2022
|
John L Higgins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,923
-0.57%
|
$728,529
$123.68 P/Share
|
Feb 15
2022
|
Matthew W Foehr |
SELL
Payment of exercise price or tax liability
|
Direct |
3,546
-0.68%
|
$436,158
$123.68 P/Share
|
Feb 15
2022
|
Charles S Berkman |
SELL
Payment of exercise price or tax liability
|
Direct |
1,578
-1.67%
|
$194,094
$123.68 P/Share
|
Jan 26
2022
|
Matthew W Foehr |
SELL
Payment of exercise price or tax liability
|
Direct |
5,125
-1.44%
|
$579,125
$113.68 P/Share
|
Jan 26
2022
|
Matthew W Foehr |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+3.55%
|
-
|
Jan 26
2022
|
Charles S Berkman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,156
-3.21%
|
$243,628
$113.68 P/Share
|
Jan 26
2022
|
Charles S Berkman |
BUY
Grant, award, or other acquisition
|
Direct |
6,237
+8.72%
|
-
|
Jan 26
2022
|
John L Higgins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,243
-1.3%
|
$1,044,459
$113.68 P/Share
|
Jan 26
2022
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,166
+3.18%
|
-
|
Jan 26
2022
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,628
-3.59%
|
$409,964
$113.68 P/Share
|
Jan 26
2022
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
11,651
+10.76%
|
-
|